Taken together, these findings indicate that upregulation of PDE1, especially PDE1C in humans, plays a role in the structural remodelling process underlying PAH and, thus, offers a novel therapeutic target. The gene discussed is PDE1C; the disease is pulmonary arterial hypertension.